Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Epimedium Prenylflavonoids Extract in Healthy Men
NCT02931305Phase 1Unknown
- Sponsor
- National University Hospital
- Start
- Oct 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoporosis and cardiovascular disease (CVD) comparing Epimedium Prenylflavonoids Extract with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events/serious adverse events. Status: unknown.
02
Drugs
epimedium total flavonoids
03
Conditions
osteoporosiscardiovascular disease (CVD)
Beyond the preview
Go deeper on NCT02931305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02931305.